Ranbaxy could find buyers for its generic Lipitor rights, says analyst
This article was originally published in Scrip
Is Ranbaxy Laboratories working on a Plan B aimed at relinquishing exclusivity rights for a generic version of Pfizer's Lipitor (atorvastatin) this November in the US , should it fail to resolve long-running regulatory issues with the US FDA on time?
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.